Drugs / ShA9
ShA9
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06504160 | May 2025 → Dec 2026 expected | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03151148 | Sep 2017 → May 2019 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ShA9 | “The present study investigated the safety and mechanisms of action of Staphylococcus hominis A9 (ShA9), a bacterium isolated from healthy human skin, as a topical therapy for AD.” PMID 33619370 ↗ Feb 2021 |
| Known as | S. hominis A9 | “This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical...” NCT06504160 ↗ |
| Known as | Staphylococcus Hominis A9 | “Safety and Efficacy of Topical Bacteriotherapy for Atopic Dermatitis Using Staphylococcus Hominis A9” NCT06504160 ↗ |
| Action | Inhibit | “ShA9 killed S. aureus on the skin of mice and inhibited expression of a toxin from S. aureus (psmα) that promotes inflammation.” PMID 33619370 ↗ Feb 2021 |
| Modality | Other / unclassified | “a bacterium isolated from healthy human skin” PMID 33619370 ↗ Feb 2021 |
| Route | Topical | “topical application administered twice daily for one week.” NCT03151148 ↗ |